Clinical Trial Update: Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose naltrexone for relapse prevention in adults with major depressive disorder; the study completed and posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Naltrexone (low-dose) (naltrexone)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Major Depressive Disorder, Depression, Unipolar | Phase 2 | Status: COMPLETED | Results posted: 2017-02-24